- All
- 2026-06-11 [Thursday]
- 2026-06-12 [Friday]
- 2026-06-13 [Saturday]
- 2026-06-14 [Sunday]
- All
- A1-A (102-107)
- A1-A101
- A1-A102
- A1-A103
- A1-A104
- A1-A (105-107)
- A1-A108
- A1-A109
- A1-A110
- A2-A206
- A2-A207
- A2-A208
- A2-A213
- A2-A214
- A2-A215
- B1 Hall (Poster Area)
- B1 Hall (Exhibition Area)
2026-06-11 (Thursday)
A1-A108
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 17:17-17:25 |
From Unresectable to R0 Resection: Successful Conversion Therapy with "Intervention + T+A" for Synchronous Liver and Gastric Cancers |
Yang Zhao | |
| 2 | 17:25-17:33 |
Case Report: Conversion Therapy Using "T+A" Combined with TACE for Intermediate-to-High Burden Unresectable Hepatocellular Carcinoma |
Jian Zhang | The Second Affiliated Hospital of Soochow University, China |
| 3 | 17:33-17:41 |
Trans-arterial Chemoembolization Combined with l Liver Venous Deprivation“Dual Conversion” versus TACE Alone in Hepatocellular Carcinoma with Insufficient Future Liver Remnant: A Real-World Retrospective Cohort Study |
Ying Yang | West China Hospital, Sichuan University, China |
| 4 | 17:41-17:49 |
Clinical Efficacy and Prognostic Factors of Atezolizumab Plus Bevacizumab Combined with On-demand Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma |
Jin-Peng Li | Shandong Cancer Hospital and Institute, China |
| 5 | 17:49-17:57 |
Efficacy and Survival Outcomes of Locoregional Therapy Combined with Targeted-Immune Triplet Therapy for Conversion Surgery in Initially Unresectable Hepatocellular Carcinoma |
Ning Ai | The Fourth Hospital of Hebei Medical University, China |
| 6 | 17:57-18:09 |
Panel Discussion |
A LL | |
| 7 | 18:09-18:14 |
Conclusion |
Hai-Peng Yu | Tianjin Medical University Cancer Institute & Hospital, China |
| 8 | 18:09-18:14 |
Conclusion |
Xiang-Qing Kong | Jiangsu Province Hospital, China |
